VivoSeq
Gastroenterology

Fecal Incontinence

18

Pipeline Programs↗

6

Active Trials↗

10

Companies Involved↗

Fecal Incontinence is an emerging landscape with 18 programs across 10 companies. The most active players are GSK, RDD Pharma Ltd, Astellas. 2 therapies are approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

11/100

Mech. Concentration

20/100

Completion Rate

57/100

Attrition Rate

26/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 1R

RDD Pharma Ltd

3 programs

Phase 2Astellas logo

Astellas

1 program

Phase 2K

Kenvue Brands

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

17 of 19 classified programs — the dominant modality here.

11%ALL OTHERSCell therapy211%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 96% of 25 pipeline programs.

Analysis

Trial Status

23

clinical trials

Completed8 · 35%
Withdrawn3 · 13%
Terminated3 · 13%
Unknown status3 · 13%
Active, not recruiting2 · 9%
Not yet recruiting2 · 9%
Other2 · 9%

Clinical Trials

Trial Activity

23 trials

Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence: a Phase III, Randomized, Controlled, Double Blind, Two Armed Clinical Study
Recruiting·IInnovacell GmbH·Phase 3·NCT04976153·290 enrolled
Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent
Recruiting·UUniversity of Alberta·Preclinical·NCT07524439·60 enrolled
Implantation of BioSphincter TM for Treatment of Severe Passive Fecal Incontinence
Active, not recruiting·CCellf Bio LLC·Phase 1·NCT05616208·10 enrolled
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
Active, not recruiting·—·Phase 3·NCT05776277·200 enrolled
Intra-rectal Botulinum Toxin Injection for Intractable Non-retentive Fecal Incontinence in Children - an Open Label Pilot Study
Not yet recruiting·SShaare Zedek Medical Center·Phase 1·NCT06785844·14 enrolled
Post-Market Clinical Follow-up Study of the Rechargeable Axonics SNM System INS Model 5101 (R20) for the Indication of Fecal Incontinence (FI)
Not yet recruiting·AAxonics, Inc.·N/A·NCT07499258·55 enrolled
Effect of MiniGo As Add-on to Oral Laxatives for Children with Constipation and Fecal Incontinence
Completed·UUniversity of Aarhus·N/A·NCT05570318·50 enrolled
A Placebo-Controlled Study of Clonidine for Fecal Incontinence.
Completed·MMayo Clinic·Phase 2·NCT00884832·44 enrolled
A Study of Colesevelam in Fecal Incontinence
Completed·MMayo Clinic·Phase 3·NCT02628626·88 enrolled
Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence
Completed·US Department of Veterans Affairs·Phase 2/3·NCT00727649·80 enrolled
Effect and Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence
Completed·UUniversity Hospital, Rouen·Phase 3·NCT02414425·200 enrolled
Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study
Completed·YYonsei University·Phase 1·NCT02384499·21 enrolled
Autologous Cell Therapy for Treatment of Fecal Incontinence
Completed·—·Phase 1/2·NCT01600755·53 enrolled
The Role of Fiber in the Prevention and Treatment of Fecal Incontinence
Completed·MMassachusetts General Hospital·Preclinical·NCT04806386·31 enrolled
Educational-Medical-Behavioral Treatment of Fecal Incontinence
Terminated·UUniversity of North Carolina, Chapel Hill·N/A·NCT01717456·31 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)